Mozobil contains the active substance plerixafor which blocks a
protein on the surface of blood stem cells. This protein “ties”
blood stem cells to the bone marrow. Plerixafor improves the
release of stem cells into the blood stream (mobilisation). The
stem cells can then be collected by an apheresis machine, and
subsequently frozen and stored until your transplant.
If mobilisation is poor, Mozobil is used to help collect blood stem
cells for transplantation in patients with lymphoma (a cancer of
the white blood cells) and multiple myeloma (a cancer that affects
plasma cells in the bone marrow).

DO NOT use Mozobil
• if you are allergic (hypersensitive) to plerixafor or any of the
other ingredients of Mozobil (listed in section 6, ‘What Mozobil
contains’)
Take special care with Mozobil
Tell your doctor:
• if you have or have had any heart problems.
• if you have kidney problems. Your doctor may adjust the dose.
• if you have high white blood cell counts.
• if you have low platelet counts.
• if you have a history of feeling faint or lightheaded on standing
or sitting or have fainted before upon injections.
• if you are under 18 years of age. The effects of Mozobil on
children and adolescents have not been studied.
Your doctor may perform regular blood tests to monitor your
blood cell count.
It is not recommended to use Mozobil for stem cell mobilisation if
you have leukaemia (a cancer of the blood or bone marrow).
Using other medicines
Please tell your doctor or pharmacist if you are taking or have
recently taken any other medicines, including medicines obtained
without a prescription.
Pregnancy and breast-feeding
You should not use Mozobil if you are pregnant, since there is no
experience with Mozobil in pregnant women. It is important to
tell your doctor if you are, think you may be or are planning to
become pregnant. It is recommended to use contraception if you
are of child-bearing age.
You should not breast-feed if you are using Mozobil, since it is not
known if Mozobil is excreted in human milk.

Driving and using machines
Mozobil may cause dizziness and fatigue. Therefore, you should
avoid driving if you feel dizzy, tired or unwell.
Important information about some of the ingredients of
Mozobil
Mozobil is essentially sodium-free. It contains less than 1 mmol
sodium (23 mg) per dose.

Your medicine will be injected by a doctor or a nurse.
You will first receive G-CSF, then you will be given Mozobil
Mobilisation will be started by first giving you another medicine
called G-CSF (granulocyte-colony stimulating factor). G-CSF will
help Mozobil to work properly in your body. If you want to know
more about G-CSF ask your doctor and read the corresponding
package leaflet.
How much Mozobil is given?
The usual dose is 0.24 mg/kg body weight/day. Your Mozobil
dose will depend on your body weight, which should be measured
the week before you receive your first dose. If you have moderate
or severe kidney problems, your doctor will reduce the dose.
How is Mozobil given?
Mozobil is given by subcutaneous injection (under your skin).
When is Mozobil given for the first time?
You will receive your first dose of Mozobil 6 to 11 hours before
apheresis (collection of your blood stem cells).
How long will Mozobil be given?
Treatment with Mozobil lasts 2 to 4 consecutive days (in some
cases up to 7 days), until enough stem cells have been collected
for your transplant. In a few cases, enough stem cells may not be
collected, and the collection attempt will be stopped.

Like all medicines, Mozobil can cause side effects, although not
everybody gets them.
Please tell your doctor immediately if
• shortly after receiving Mozobil, you experience rash, swelling
around the eyes, shortness of breath or lack of oxygen, feeling
lightheaded on standing or sitting, feeling faint or fainting.
• you have pain in the upper left abdomen (belly) or at the tip of
your shoulder.
Side effects may occur with certain frequencies, which are
defined as follows:
• very common: affects more than 1 user in 10
• common: affects 1 to 10 users in 100
• uncommon: affects 1 to 10 users in 1,000
• rare: affects 1 to 10 users in 10,000
• very rare: affects less than 1 user in 10,000
• not known: frequency cannot be estimated from the available
data.

Very common side effects
• diarrhoea, nausea (feeling sick), injection site redness or
irritation
Common side effects
• headache
• dizziness, feeling tired or unwell
• difficulty in sleeping
• flatulence, constipation, indigestion, vomiting
• stomach symptoms such as pain, swelling or discomfort
• dry mouth, numbness around the mouth
• sweating, generalised redness of the skin, joint pains, pains in
muscles and bones.
Uncommon side effects
• allergic reactions such as skin rash, swelling around the eyes,
shortness of breath
Rarely, gastrointestinal side effects may be severe (diarrhoea,
vomiting, stomach pain and nausea).
Heart attacks
In clinical trials, patients with risk factors for a heart attack
uncommonly suffered heart attacks after being given Mozobil and
G-CSF. Please inform your doctor immediately if you experience
chest discomfort.
Pins and needles and numbness
Pins and needles and numbness are common in patients being
treated for cancers. About one in five patients suffered from these
feelings. However, these effects do not seem to occur more
frequently when you use Mozobil.
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet, please tell your doctor or nurse.

Keep out of the reach and sight of children.
Do not use Mozobil after the expiry date which is stated on the
carton and vial.
This medicinal product does not require any special storage
conditions.
After opening the vial, Mozobil should be used immediately.
Medicines should not be disposed of via wastewater or household
waste. The pharmacist will dispose of medicines no longer
required. These measures will help to protect the environment.